School of Clinical Medicine
Centre of Cancer Medicine

Director
Professor Rina Hui
Clinical Professor and Director, Centre of Cancer Medicine

Professor Rina Hui assumes Directorship of the Centre of Cancer Medicine in January 2023. She is a well-established medical oncologist specialising in breast and lung cancers as well as a passionate educator.

After completing her medical degree at The University of Sydney and specialist training at The Royal North Shore Hospital, Rina undertook translational research in cyclin D1-CDK4/6-p16INK4a-pRb pathway in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Before joining HKU, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at the Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. She served as Co-Chair of the Oncology Block teaching at the University of Sydney and served in the written examination committee for the Royal Australasian College of Physician. She was also the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group, a member of the Breast Cancer Trials and the Thoracic Oncology Group of Australasia. Rina was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. Rina has been principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy and targeted therapies in breast and lung cancers over the years resulting in publications in highly ranked journals.

10 MOST SIGNIFICANT PUBLICATIONS:

1. Pembrolizumab for the Treatment of Non-small Cell Lung Cancer (Times cited: ~5,560)
   
   Edward Garon, Naiyer Rizvi, Rina Hui, Natasha Leighl, Ani Balmanoukian, Joseph Elder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew Hellmann, Omid Hamid, Jonathan Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi.
   
   New England Journal of Medicine, 372 (21):2018-2028, 2015.
   
   
2. Pembrolizumab versus Chemotherapy for PD-L1-positive Non-small Cell Lung Cancer (Times cited: ~7,863)
   
   Martin Reck, Delvys Rodriguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Gsoszi, Andrea Fulip, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lbiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer
   
   New England Journal of Medicine, 375(19):1823-1833, 2016.
   
   
3. Pembrolizumab as First-line Therapy for Patients with PD-L1-positive Advanced Non-small Cell Lung Cancer: a Phase 1 Trial
   
   R. Hui, E.B. Garon, J.W. Goldman, N.B. Leighl, M.D. Hellmann, A. Patnaik, L. Gandhi, J.P. Eder, M.-J. Ahn, L. Horn, E. Felip, E. Carcereny, R. Rangwala, G.M. Lubiniecki, J. Zhang, K. Emancipator, C. Roach, N.A. Rizvi
   
   Annals of Oncology, 28(4): 874-881, 2017.
   
   
4. Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer (Times cited: ~3,189)
   
   S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.-C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Wadsworth, G. Melillo, H. Jiang, Y. Huang, P.A. Dennis, and M. Ozguroglu, for the PACIFIC Investigators.
   
   New England Journal of Medicine, 377(20): 1919-1929, 2017.
   
   
5. Pembrolizumab plus Chemotherapy in Metastatic Non-small Cell Lung Cancer (Times cited: ~4,398)
   
   L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y. –S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, M.C. Garassino for the KEYNOTE-189 Investigators.
   
   New England Journal of Medicine, 378 (22): 2078-2092, 2018.
   
   
6. Overall Survival with Durvalumab after Chemoradiotherapy for Stage III NSCLC (Times cited: ~2,102)
   
   S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.-C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D. Spigel, C. Wadsworth, G. Melillo, M. Taboada, P.A. Dennis, and M. Ozguroglu, for the PACIFIC Investigators.
   
   New England Journal of Medicine, 379 (24): 2342-2350, 2018.
   
   
7. Patient-Reported Outcomes with Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study
   
   Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Jhanelle E. Gray, Anna Rydén, Louis Viviers, Lynne Poole, Yiduo Zhang, Phillip A. Dennis, and Scott J. Antonia
   
   Lancet Oncology, 20:1670-1680, 2019.
   
   
8. Lucitanib for the Treatment of HR⁺/ HER2^-  Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
   
   Rina Hui*, Alex Pearson*, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, J.M. Perez-Garcia, Philippe Aftimos, Philippe Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas Turner, Fabrice Andre, Giuseppe Curigliano. (*Equal first authors)
   
   Clinical Cancer Research, 26: 354-363, 2020.
   
   
9. Pembrolizumab for Early Triple-Negative Breast Cancer (Times cited: ~1,181)
   
   P. Schmid, J. Cortes, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P.A. Fasching, F. Cardoso, M. Untch, L. Jia, V. Karantza, J. Zhao, G. Aktan, R. Dent and J. O’Shaughnessy, for the KEYNOTE-522 Investigators
   
   New England Journal of Medicine, 382: 810-821, 2020
   
   
10. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
    
    P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kummel, J Bergh, C Denkert, Y H Park, R Hui, N Harbeck, M Takahashi, M Untch, PA Fasching, F Cardoso, J Andersen, D Patt, M Danso, M Ferreira, M A Mouret-Reynier, S A Im, J H Ahn, M Gion, S Baron-Hay, J F Boileau, Y Ding, K Tryfonidis, G Aktan, V Karantza, J O’Shaughnessy
    
    New England Journal of Medicine, 386: 556-567, 2022
    

h-index: 60; Citations: 36122

The current standard of cancer care involves multimodality treatment, including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. With 120-years history of success in cancer treatment, radiotherapy plays a very important role in survival extension and quality of life improvement in cancer patients.

Radiation oncology is a technology-based medical specialty that uses radiation from medical devices to treat cancer. There are constant technology advances involved in all facets of radiotherapy, including treatment decision making, imaging-guided simulation, delineation of tumor targets and organs at risk (OARs), dose fractionation prescription, treatment plan optimisation, plan quality assurance, treatment delivery, multi-disciplinary integration with other therapies, as well as outcome prediction and assessment. Thereby, Advanced Technology in Radiation Oncology (ATRO) Programme is initiated to:

~ Conduct translational and clinical research in advanced technology of radiotherapy including artificial intelligence impactful to the treatment outcome of cancer patients in the era of multidisciplinary care. 

~ Ensure the quality of radiotherapy, thereby minimising the confounding effects to other cancer treatment modalities in clinical trials.

~ Set up a multidisciplinary and cross-field collaborative platform for Radiation Oncologists / Clinical Oncologists, Medical Physicists and Radiation Technologists with 1) Scientists in biology, physics, engineering and computing science, and 2) Clinicians of other disciplines like radiology, pathology, surgery and medical oncology in research and clinical practice.

~ Train professionals in ATRO and provide educational courses to clinicians, researchers, students, patients and care givers as well as general public on ATRO with inclusion of multidisciplinary integration.

SELECTED LIST OF RADIATION TECHOLOGY

Image Guided Radiation Therapy (IGRT) 4D Radiation Therapy (4DRT)

Intensity Modulated Radiation Therapy (IMRT) 

Volumetric Modulated Arc Therapy (VMAT) including Tomotherapy

Stereotactic Body Radiotherapy (SBRT) Stereotactic Radiosurgery (SRS)

PET in Radiation Therapy (PET-RT)

Spatially Fractionated Radiation Therapy (SFRT)

Adaptive Radiation Therapy (ART)

Biology Guided Adaptive Radiation Therapy (BiGART)

Particle Therapy: Proton Beam, Heavy Ions, and Neutron Therapy

Ultra-High Dose Rate (FLASH) Radiotherapy (FLASH-RT)

Big Data and Artificial Intelligence (AI)

ATRO Programme Director: Feng-Ming (Spring) Kong, MD, PhD, FACR, FAAWR, FASTRO

Questions and job opportunities: Please contact atrop@hku.hk

Email: cancermed@hku.hk